The following article features coverage from the American Urological Association (AUA) 2019 meeting. Click here to read more of Renal & Urology News’ conference coverage.

CHICAGO—Radiation therapy (RT) delivered to the primary tumor in men with metastatic castration-resistant prostate cancer (mCRPC) is safe and feasible, and it may be associated with improved survival, investigators concluded in a presentation at the 2019 American Urological Association annual meeting.

Naoki Fujita, MD, of the Hirosaki University Graduate School of Medicine in Hirosaki, Japan, studied 93 men with mCRPC, of whom 32 (34%) received RT (at 70 Gy) to the primary tumor after their CRPC diagnosis and 61 (66%) did not. On multivariable analysis, RT was significantly associated with a 72% decreased risk of death from any cause, but not with cancer-specific mortality.

The study population had a median age at CRPC diagnosis of 74 years. Of the 93 men, 81% had metastases to the bone, 28% to the lymph nodes, and 6.3% to the lungs. Concomitant medications with RT included abiraterone (28%), flutamide (13%), estramustine (13%), enzalutamide (9%), docetaxel (9%), and other medications (13%); 16% received no other therapy.

The median follow-up duration was 24 months, and the median time from CRPC diagnosis to RT was 11 months. The RT group had a median PSA decline of 18%, with 13 patients (41%) experiencing a 30% or greater decrease in PSA.

In the RT arm, the rates of RT-related adverse events of any grade and grade 3 or higher were 56% and 19%, respectively.

Read more of Renal & Urology News’ coverage of the AUA 2019 meeting by visiting the conference page.

Reference

Fujita N, Momota M, Tobisawa Y, et al. The efficacy and feasibility of radiation therapy to the primary tumor in patients with metastatic castration resistant prostate cancer. Presented at the 2019 American Urological Association annual meeting held May 3-6 in Chicago. Abstract PD15-03.